· STEQEYMA® (ustekinumab-stba) is Celltrion’s biosimilar to STELARA® (ustekinumab), which was launched on March 12, 2025 · Celltrion’s adalimumab-aaty was previously added to the Costco Member Prescription Program in August 2024 JERSEY CITY, N.J., March 27, 2025 – Celltrion, Inc., today announced that STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab) has been added to the Costco Member […]
· STEQEYMA®, one of the first-wave biosimilars to STELARA®, is now available in the U.S. · Approved for the same indications as the reference product, STEQEYMA will be priced with a wholesale acquisition cost (WAC) list price at an 85% discount to the current WAC list price of STELARA to help improve patient access to high-quality biologic […]
· OMLYCLO® (omalizumab-igec) is the first and only omalizumab biosimilar approved by the FDA · Regulatory approval for interchangeability was supported by positive phase III data demonstrating comparable efficacy and safety profile with the reference product XOLAIR® (omalizumab)[1] · The availability of the first omalizumab biosimilar will help increase access and potentially lower the healthcare cost for people […]
· STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) are approved by FDA for all indications of reference products PROLIA® (denosumab) and XGEVA® (denosumab) respectively[1], [2] · The FDA approval is based on robust clinical evidence, which show no clinically meaningful differences from the reference products · With the FDA approval of STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) Celltrion’s biosimilar portfolio […]
– The intravenous (IV) formulation of AVTOZMA® (tocilizumab-anoh) is expected to be available in the U.S. in August 2025 – Approval was received for multiple indications, including rheumatoid arthritis (RA), giant cell arteritis (GCA), polyarticular juvenile idiopathic arthritis (pJIA), systemic juvenile idiopathic arthritis (sJIA) and COVID-19[1] – AVTOZMA® becomes Celltrion’s fifth immunology biologic and seventh […]
– STEQEYMA (CT-P43) is approved for both adult and pediatric patients with plaque psoriasis (PsO) and active psoriatic arthritis (PsA) as well as adults with Crohn’s disease (CD) and ulcerative colitis (UC) – STEQEYMA is a strategic addition to Celltrion’s portfolio, expanding the portfolio and building on Celltrion’s expertise in immunology – STEQEYMA is expected to be marketed […]